Mahajan Supriya, Mahajan Saurabh, Patgiri Sayashree
Department of Microbiology, School of Medical Sciences and Research, Sharda University, Greater Noida 201306, Uttar Pradesh, India.
Department of Neurosurgery, Max Superspeciality Hospital, Patparganj, New Delhi 110092, India.
Viruses. 2025 Jun 26;17(7):903. doi: 10.3390/v17070903.
Despite the significant decrease in SARS-CoV-2-related mortality, COVID-19 continues to impose a high public health burden due to the high rate of post-COVID-19 pathological conditions, broadly termed Long COVID, that continue for any period of time and are generally multisystemic. However, recent studies have strengthened the evidence that the reactivation of the Epstein-Barr virus (EBV) in the post-COVID-19 era has significantly contributed to the exacerbation and prolongation of Long COVID symptoms. The mechanism and pathophysiology of EBV reactivation in Long COVID patients still need further exploration due to limited studies. This review summarises the various studies linking EBV reactivation in Long COVID along with its pathophysiology and novel therapeutics for EBV in a post-COVID-19 era.
尽管与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)相关的死亡率显著下降,但由于新冠后病理状况(统称为“长新冠”)发生率高,新冠病毒病(COVID-19)继续给公共卫生带来沉重负担。这些病理状况会持续一段时间,通常涉及多个系统。然而,最近的研究进一步证明,在新冠后时代,爱泼斯坦-巴尔病毒(EBV)的重新激活显著加剧并延长了长新冠症状。由于研究有限,长新冠患者中EBV重新激活的机制和病理生理学仍需进一步探索。本综述总结了各种将长新冠中EBV重新激活与其病理生理学以及新冠后时代EBV新疗法联系起来的研究。